186 related articles for article (PubMed ID: 33668794)
1. The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib.
Robak P; Jarych D; Mikulski D; Dróżdż I; Węgłowska E; Kotkowska A; Misiewicz M; Smolewski P; Stawiski K; Fendler W; Szemraj J; Robak T
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668794
[TBL] [Abstract][Full Text] [Related]
2. The resistance mechanisms of proteasome inhibitor bortezomib.
Lü S; Wang J
Biomark Res; 2013 Mar; 1(1):13. PubMed ID: 24252210
[TBL] [Abstract][Full Text] [Related]
3. The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma.
Maneix L; Sweeney MA; Lee S; Iakova P; Moree SE; Sahin E; Lulla P; Yellapragada SV; Tsai FTF; Catic A
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33671345
[TBL] [Abstract][Full Text] [Related]
4. Carfilzomib in Combination with Bortezomib Enhances Apoptotic Cell Death in B16-F1 Melanoma Cells.
Lee MS; Lim SH; Yu AR; Hwang CY; Kang I; Yeo EJ
Biology (Basel); 2021 Feb; 10(2):. PubMed ID: 33671902
[TBL] [Abstract][Full Text] [Related]
5. Endoplasmic reticulum stress and proteasome inhibitors in multiple myeloma: room for improvement.
Kubicki T; Gil L; Dytfeld D
Pol Arch Intern Med; 2021 Apr; 131(4):361-368. PubMed ID: 33768999
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma.
Hirano M; Imai Y; Kaito Y; Murayama T; Sato K; Ishida T; Yamamoto J; Ito T; Futami M; Ri M; Yasui H; Denda T; Tanaka Y; Ota Y; Nojima M; Kamikubo Y; Gotoh N; Iida S; Handa H; Tojo A
J Exp Clin Cancer Res; 2021 Mar; 40(1):110. PubMed ID: 33757580
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice.
Fogli S; Galimberti S; Gori V; Del Re M; Danesi R
Pharmacol Res; 2021 May; 167():105537. PubMed ID: 33684510
[TBL] [Abstract][Full Text] [Related]
8. Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.
Offidani M; Corvatta L; Morè S; Nappi D; Martinelli G; Olivieri A; Cerchione C
Front Oncol; 2020; 10():624661. PubMed ID: 33680948
[TBL] [Abstract][Full Text] [Related]
9. [The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma].
Liu J; He HY; Li L; Lu J; Qiang WT; Guo P; Hou N; Jiang H; Du J; Fu WJ
Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):27-32. PubMed ID: 33677865
[No Abstract] [Full Text] [Related]
10. Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-κB signaling.
Su Z; Han S; Jin Q; Zhou N; Lu J; Shangguan F; Yu S; Liu Y; Wang L; Lu J; Li Q; Cai L; Wang C; Tian X; Chen L; Zheng W; Lu B
Cell Death Dis; 2021 Mar; 12(3):251. PubMed ID: 33674562
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma.
Blommestein HM; Franken MG; van Beurden-Tan CHY; Blijlevens NMA; Huijgens PC; Sonneveld P; Uyl-de Groot CA; Zweegman S
JAMA Netw Open; 2021 Mar; 4(3):e213497. PubMed ID: 33779744
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma.
Zeng X; Liu Q; Peng L; Peng Y; Yi L; Luo X; Li S; Wan X; Tan C
Adv Ther; 2021 May; 38(5):2379-2390. PubMed ID: 33770365
[TBL] [Abstract][Full Text] [Related]
13. New biomarker for lung cancer - focus on circSETD3.
Tao F; Gu C; Li N; Ying Y; Cao LF; Xiao QF; Ni D; Zhuang YB; Zhang Q
J Biol Regul Homeost Agents; 2021; 35(2):583-591. PubMed ID: 33768996
[TBL] [Abstract][Full Text] [Related]
14. R-CHOP compared to R-CHOP + X for newly diagnosed diffuse large B-cell lymphoma: a systematic review and meta-analysis.
Pasvolsky O; Rozental A; Raanani P; Gafter-Gvili A; Gurion R
Acta Oncol; 2021 Jun; 60(6):744-749. PubMed ID: 33734921
[TBL] [Abstract][Full Text] [Related]
15. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulators in newly diagnosed multiple myeloma: current and future concepts.
Delforge M; Vlayen S; Kint N
Expert Rev Hematol; 2021 Apr; 14(4):365-376. PubMed ID: 33733978
[No Abstract] [Full Text] [Related]
17. Novel Experimental Drugs for Treatment of Multiple Myeloma.
Offidani M; Corvatta L; Morè S; Olivieri A
J Exp Pharmacol; 2021; 13():245-264. PubMed ID: 33727866
[TBL] [Abstract][Full Text] [Related]
18. Real-World Outcomes With Generic Pomalidomide in Relapsed Refractory Multiple Myeloma-Experience From a Tertiary Care Cancer Center.
Bondili SK; Bagal B; Zawar A; Ventrapati P; Thorat J; Gokarn A; Punatar S; Nayak L; Bonda A; Jain H; Sengar M; Khattry N
JCO Glob Oncol; 2021 Mar; 7():361-367. PubMed ID: 33689483
[TBL] [Abstract][Full Text] [Related]
19. [POEMS syndrome: Diagnosis, stratification, treatments].
Talbot A; Jaccard A; Arnulf B
Rev Med Interne; 2021 May; 42(5):320-329. PubMed ID: 33678446
[TBL] [Abstract][Full Text] [Related]
20. [Central nervous system toxicity caused by bortezomib: five case reports and a review of literature].
Liu JH; Fan HS; Deng SH; Sui WW; Fu MW; Yi SH; Huang WY; Li ZJ; Zhang CX; Zou DH; Zhao YZ; Qiu LG; An G
Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):63-69. PubMed ID: 33677871
[No Abstract] [Full Text] [Related]
[Next] [New Search]
